Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticleRESEARCH ARTICLE

The Effects of Autoclaving on the Stability of Physostigmine Salicylate in Buffer Solutions

Shirley T. Yang and Leon 0. Wilken
PDA Journal of Pharmaceutical Science and Technology March 1988, 42 (2) 62-67;
Shirley T. Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leon 0. Wilken
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

The effects of autoclaving on the stability of physostigmine salicylate in buffer solutions of pH 3.0, 4.0, and 5.3 were studied by reversed-phase, ion-pairing liquid chromatography. The influences of flushing the solutions with N2 and adding NaHSO3 to the solutions on the stability of physostigmine in pH 4.0 buffer solutions were also studied by this HPLC method. The anaerobic (N2 flushed) pH 3.0 buffer solutions retained 98.2% of physostigmine and the aerobic (without N2 flushing) pH 3.0 buffer solutions retained 95.4% of physostigmine after autoclaving at 123° C for 25 minutes. As the autoclaving time was reduced to 15 minutes, 99.5% of physostigmine remained in the anaerobic solutions of pH 3.0. For pH 4.0 anaerobic solutions of physostigmine salicylate, the addition of NaHSO3 lowered the average percent of remaining physostigmine after autoclaving at 123° C for 25 minutes from 89.1% to 88.3%. But both values are significantly greater than the average percent of physostigmine remaining in pH 4.0, aerobic solutions without NaHSO3, which is 87.5% and that in the similar solution but with NaHSC3, which is 85.7%. The anaerobic pH 5.3 buffer solutions retained 28.0% of physostigmine after autoclaving at 123°C for 15 minutes. No detectable amount of physostigmine remained in the unbuffered solutions either of aerobic or anaerobic conditions after autoclaving. Eseroline was the only decomposition product detected in the anaerobic, unbuffered solutions; both eseroline and rubreserine were detected in the aerobic, unbuffered solutions of physostigmine salicylate after autoclaving. The isocatalytic point for physostigmine at 123° C was calculated to be 2.79 from the base-catalyzed hydrolysis rate constant obtained in this study.

  • Received October 30, 1987.
  • Accepted February 3, 1988.
  • Copyright © Parenteral Drug Association. All rights reserved.

PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.  

If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing. 

Full issue PDFs are for PDA members only.

Note to pda.org users

The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

Full issue PDFs are for PDA members only. You can join PDA at www.pda.org. 

PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology
Vol. 42, Issue 2
March-April 1988
  • Table of Contents
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effects of Autoclaving on the Stability of Physostigmine Salicylate in Buffer Solutions
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
17 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Effects of Autoclaving on the Stability of Physostigmine Salicylate in Buffer Solutions
Shirley T. Yang, Leon 0. Wilken
PDA Journal of Pharmaceutical Science and Technology Mar 1988, 42 (2) 62-67;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Effects of Autoclaving on the Stability of Physostigmine Salicylate in Buffer Solutions
Shirley T. Yang, Leon 0. Wilken
PDA Journal of Pharmaceutical Science and Technology Mar 1988, 42 (2) 62-67;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Monitoring of Mannitol Phase Behavior during Freeze-Drying Using Non-Invasive Raman Spectroscopy
  • Long-Term Stabilization of a New Freeze-Dried and Albumin-Free Formulation of Recombinant Human Interferon Alpha 2b
  • Pharmaceutical Development of an Intravenous Dosage Form of Diacetylmorphine Hydrochloride
Show more Research Article

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2023 PDA Journal of Pharmaceutical Science and Technology ISSN: 1079-7440

Powered by HighWire